Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
FYI.. follow up to the Phyton patent application @ USPTO
As of 8/14/2020 under Notice of Allowance and Fees Due..
" This application identified above has been examined and is allowed for issuance as a patent"
" The issue fee and Publication fee (if required) must be paid within three months from the mailing date of this notice or the application shall be regarded as abandoned"
The fee is $500.00 usd.
Statement from PHYTON BIOTECH in their appeal..
At present Thapsia garganica plants are the only reasonable source of the compound thapisgargan because due to the complex chemical structure of this compound, it cannot be chemically synthesized at an economically reasonable price"
There may be other factors but a PH III mipsagargin trial would need an abundance of thapsigargin which at present is economical unreasonable. This will soon change as Phyton has cleared last hurdle for the issue of their production patent. In the end Mipsagargin may just be a classic timing issue as NSPX has managed to stay alive until certain factors align in place.
FYI.. the patent application #15/100,780 submitted by Phyton for the "Production of Thapisgargin by Thapsia Cell Suspension Culture" which was originally rejected by examination is now back moving forward. The rejection was reversed under appeal by Phyton on 8/7/2020. It seem that a commercially low cost production of thapsigargin is finally on it's way to the medical community. Phyton is the wolds largest producer of Taxol a cancer chemo drug derived from the bark of the Pacific Yew tree. A WHO designated essential drug.
Low volume no interest slide. Scant sellers into the low ball bid. Waiting?
Only communication at all from NSPX has come in the filings. The 2nd quarter 10-Q is due this week (8/14). If the filing comes out there is always a chance of some pertinent information. Lately they have been boiler plate but anything is possible because Covid-19 has the entire sector in a search for effective medicines. The posts have turned negative so that is a good sign that something positive may happen.
Correct..the major dilution and maxing out OS followed by another RS as some have predicted need some buyers with cash to drive the ticker. Anemic volume won't accomplish the task. The covid-19 hype has already been played and fizzled.. the cancer cure is still out there but has been shelved..Ridgeway seems to be a cold case..nothing has been said or known about MediciNova..none of the irons in the fire are working out. However, stay tuned for something coming from somewhere or maybe from nowhere to bust the ticker loose!
Yes the Cayman Island connection has always been something to suspect. Hard to understand why international private equity funds with $500,000 and $300,000 buy in minimums would want NSPX as part of their portfolio. Puzzling for sure!
I would think that Raul Silvestre (nspx attorney) would have more info. He's been around since genspera. It's hard to get info from him as others have tried in the past but he may be more forthcoming now. I still believe he is behind most of NSPX dealings. It may be or may not be a coincidence that Cain's office is 7 miles from Silvestre's and the new owner of 5000 shares of preferred stock James Dabb's office is 2 miles from Silvestre's. It may be that Silvestre is handing out some perks to his clients.
On July 26, 2019, the Company appointed Michael Cain to serve as the interim chief executive officer, chief financial officer, president, and as a member of the Board. Mr. Cain will serve on an interim basis as principal executive and financial officer on an at-will basis. The Company is not a party to any employment agreement or contract related to Mr. Cain’s employment and he will not receive any compensation at this time.
The statement when Cain was appointed ceo leads to believe that he has limited ties to nspx and may be getting paid for the service that he provides by a third party.
Yes real strange! I have always had a idea that Cain was placed as the CEO by Silvestri (NSPX lawyer). His only function is to sign as NSPX ceo and legal representative. Although he may be getting no compensation from NSPX directly he may be getting paid by the law firm to provide that service. Law firms routinely use associates and bill clients accordingly. Real hard to find some one to work for nothing.
Yes their stock would be issued at 85% of market but no matter the profits that you say would be materialized only come to fruition if there are sufficient buyers. As of now that is not the case. They were issued 130+million of stock in first quarter only because they were able to sell them easily because of covid hype. Nothing on the horizon at this time.
You would think that the off shore private hedge funds that hold a large portion of NSPX stock would be more interested in the ticker than recouping the 2.2 million owed. Interesting to see what was done with the notes due on 7/16. Regardless.. zilch will happen until volume increases..and volume won't increase until something happens!
The chase may be on its way.. the ticker may be ready to go .. a little push is all it needs.. lots of eyes looking. Make sure you got ammo to take advantage if it comes!
There is reason to believe (although nothing verified) that the reason no one can be contacted or there is no information released by anyone is that NSPX is and has been for years controlled entirely by the private equity funds Sabby Healthcare Master Fund and Sabby Volatility Warrant Master Fund. This was noted in the recent DEF14c. They are VULTURE funds managed by Sabby Management LLC. They have taken over NSPX by issuing debt to keep them alive. Behind the multiple RS to keep a recurring amount of shares available. Behind the shut down to limit unnecessary expenditures. Gag any frivolous communications. All for the purpose of holding NSPX shares in their private funds to extract by whatever means any profits that may develop. Trying to contact anyone associated with these private funds to explain their position in NSPX would most certainly be a waste of time.
They will chase this ticker up just like was done months ago.. won't be able to resist. Far from being over!
Maybe something on horizon that will increase interest like it did on March 26, 2020 when it posted 166,071,636 share trading volume. Not like today's 10,000 + shares.
Pathetic, anemic are two fair adjectives for what is happening to the volume. I could come up with a few more but those two say it all. Difficult to dilute the os when 10K shares are hard to sell let alone the millions that were bought and sold in 1st quarter. Something needs to happen to get buyers interested in the ticker.
Market Watch article surmising that Inspyr possibly had a drug that would be effective in the Covid-19 search for vaccine or cure set the HYPE ablaze. Still wonder where this article originated and what is in store for the future item or articles to get nspx moving again?
Yes .. very curious on why Cain was chosen as CEO and who was behind the decision. The initial notification was that he was hired on a temporary basis "at will" with no contract and no compensation (strange). His business Level 4 Services is based in Calabass Ca not far from the companies attorney Silvestri so that may be the connection. Regardless, he does not seem to have any biotech experience. Although there are mention of certain players Cain, Hislop, Flannery, Dabbs, Sabby, Lowe, FLG Partners, Oglivie, Thom, it is difficult to ascertain who actually has the hands on the wheel. Obviously, decisions are being made (not many) so some one or a group must be communicating the functions of the company. It is certainly a ghost ship heading to who knows where. As noted there are 133+/- current stock holders as legitimate owners of the company at various percentage. I do think all the patents and IP is wholly owned by the company and the company will never be Or wants to be an operational biotech company as envisioned by most. It started as a virtual company under Craig Dionne and remains a virtual company with no assets other than Its Intellectual Property.
Between January 1, 2020 and March 31, 2020, debenture holders converted an aggregate of $451,662.03 into 131,351,247 shares of common stock at per
share conversion prices ranging from $0.0021 to $0.47.
As with last RS most of the shares available went to Sabby converting debenture liability to shares. Sabby sold most on open market and kept what was legal for their account. This may happen again but as of now the buyers market for this stock does not exist. Once the "D" comes off the ticker (maybe soon) there may be something to increase interest in this stock.
Early on Mipsagargin got the scientifically incorrect but layman recognizable nickname "the cancer grenade". Just as a grenade is harmless to the enemy while it is in its inert stage mipsagargin likewise is harmless to healthy cells until it is activated. In the case of a grenade the motion of pulling the pin and letting go of the handle activates the explosive power of the weapon. Mipsagargin flows harmlessly thru the blood stream until it finds cells with high concentrations of PSMA (found on most solid cancer tumors). It is then that it adheres to the cancer cell releasing and activating its deadly payload toxic killer thapsigargin to annihilate the tumor.This entire process was developed at the John Hopkins Cancer Research Labs by renowned cancer PHDs. The process is also patented and the drug mipsagargin has received Orphan Drug Status by the FDA for the treatment of Liver Cancer.
Almost all of the 2.2 million of debenture debt matures 7/16/2020. Options: NSPX defaults (no way Sabby won't let it happen). NSPX pays them off (no way NSPX does not have the cash). NSPX issues Sabby enough shares @ 85% of market price and clears debt (? .. does Sabby want to convert then sell all those shares at what price?). Sabby extends the mature date for no charge (has happened before) Sabby extends mature date for a fee and issues another debenture to cover the cost of that fee (has happened before). Anyway it looks like NSPX will continue on in additional debt beholding to Sabby until something takes place so they can clear the debt.
Thapisgargin the active ingredient in mipsagargin is derived from the plant Thapsia Garganica. The plant primarily grows in northern Africa near or in proximity to the Mediterranean Sea. Thapsia Garganica for centuries has had the dubious moniker as the "DEADLY CARROT". This moniker goes back to when goods were transported by camel. As the caravans would rest the camels would be attracted to the orange flowers of the plant.. eat the plant then die. Thapsigargin is a toxic killer. Once Inspyr licenses or partners with an active pharma for the continued development of mipsagargin expect substantial achievement in cancer therapies. The prodrug may be reconfigured to be attracted by additional bio markers other than PSMA. This would increase effectiveness on additional cancer tumors. Inspyr has just done preliminary work on the eventual FDA approval and commercial acceptance of the drug.
Various studies have surfaced concerning the therapeutic value of different applications for adenosine modulators. From the benefits of receptors and antagonists the studies are encompassing diseases from cancer, lung disease, heart ailments, neurodegenerative events and chronic inflammation. Robert Thompson PHD former CEO of L&C (now Inspyr) has been noted as an expert in developing and patenting new and potent applications of adenosine. Inspyr licensed various adenosine applications to Ridgeway Therapeutics. Dr. Hislop is now controlling the avenue of development especially in innovative T-cell focused precision therapies. As of yet no news has surfaced as the progress of the development but updates may be released in the future.
Agreed that the physical development of the drug by Inspyr has discontinued. However, all the pre-clinical data, PH I and Ph II results and the FDA orphan Designation is still valid. Obviously, at this time Mipsagargin has not progressed into the valuable asset that was envisioned however timing is all important in investing so mipsagargins time may be ahead. There has not been a trove (or any) of negative scientific studies concerning the drug plus it was developed by some very smart research individuals. If you can find any negative articles on the drug please post!
Mipsagargin is a prodrug that is a solid tumor killer. It was designed by prominent cancer research doctors from John Hopkins Research hospital. The prodrug carries a toxic payload of thapsigargin that is 10 to 100 times more powerful than conventional chemo. The prodrug targets PSMA bio marker that is prevalent on solid tumors. Once the prodrug finds the bio marker it releases the thapsigargin into the tumor and kills it. The FDA has designated Mipsagargin as an orphan drug which will carry forth until 2034.
Inspyr also has a inventory of patents that were acquired from L&C pharmaceuticals in a merger. Some of the drugs from L&C are licensed to Ridgeway Therapeutics for development of their cancer therapeutic qualities. Inspyr for financial reasons have terminated the operations as for as physically developing the IP and assets it owns. However, as stated in the filings over and over it is still a viable company seeking to progress with agreements with others to expand their portfolio of IP and patents. The stock has performed poorly. RS have evaporated many of investors accounts and may still do the same. Nothing of substance has come from its efforts to execute its business plan. If you plan to invest in this stock be totally aware of where your putting your money. Obviously, nobody carries a crystal ball with them and this ticker may explode higher but also it could go out of business tomorrow. There are posters on each side of this position so pick your side and invest accordingly.
Low volume erosion.. took 21 trades to trade $2651 and one was for $1000. No reason to buy or sell just hanging out!
Old price target of $21.25 x 30.
No reason to sell at this point.. a low volume erode of PPS is frustrating but that is where we are.. $5000.00 dollar trading volume won't last with all those shares out there so something good or bad may come up! Debentures mature on July 16 if Sabby converts they will need to sell some stock. Question is who will buy!
Its not out of the realm of possibilities that Dr Hislop thru the agreement with Inspyr comes up with therapy advances through the platform of the adenosine formulations stipulated in their licensing agreement. It may take some time as COVID-19 has been center stage for all pharmaceuticals at the present time. He has a history of bringing NDA out so we may still see something develop between Ridgeway and Inspyr.
Dr. Hislop has held staff positions on various Bios. Very smart and successful! Now he is breaking out on his own with Ridgeway. Good for him. Wish him all the good fortune as President and CEO of Ridgeway Therapeutics.
Mid august unless delayed again by SEC.
At some time soon buyers will come into this ticker driving PPS higher.. be ready and be nimble.. too many unanswered questions to not have a position.
Not many buyers rushing into take a position at these prices. A massive $4800.00 worth of trading dollars on Thursday. Maybe they will wait for sub pennies to hit the buy button or maybe another virus hype will emerge to get some buying interest!
Yes..as early as next week but could be the following week. NSPX would not file the NT-10Q (late submittal)if they didn't plan to file the report.
You may be right on... 70,000 shares a day is not going to cut it so we'll see what happens to increase volume. With the whip saw that was experienced in the virus hype it's hard to think that any pump not verified by the company with filings or authorized PR would be taken seriously but anything is possible!
Stars may be lining up for some positive news in the 10-Q? No better time than right now! They could have filed NT 10-Q and then filed the 10-Q but obviously wanted the RS in the books before the 10-Q release. $4800 worth of dollar volume (todays take) is not going to make it..Sabby won't be pleased! Somebody needs to buy some shares!!
In theory that makes sense but finding investors to buy large quantities of the stock at the current price would be problematic. If they want to own the stock like you they will wait because as past performance dictates the stock has a history of dropping after the R/S. If they buy now they have a good chance of watching their account erode. If they don't buy and the stock rallies for some reason all they lose is an opportunity.
The shares may be released but there may not be a valid reason to buy them. However, I do agree that there is a certain population of the penny stock investor who believe that the lower the price is the more of a bargain the stock is. That theory has not proven to be true yet with NSPX but the ticker is still trading and the saga continues. All that NSPX is has been posted over and over again .. all the DD has come to light.. all the patents are listed but nothing has moved the needle. Only something new will change things!
MediciNova has previously announced that a new patent application for Glioblastoma (Brain Cancer) included the possibility of including Mipsagargin as a combination therapy with their drug MN-166. Now it seems that MediciNova is jumping into the COVID-19 arena also with the same MN-166 drug.
MediciNova Announces Opening of Investigational New Drug Application for MN-166 (ibudilast) for Prevention of Acute Respiratory Distress Syndrome in Patients with COVID-19